Dinah C, Ghulakhszian A, Sim SY, et al. - Via performing a retrospective multicenter interventional case series, researchers sought to examine the clinical outcomes of patients with treatment–naïve diabetic macula oedema (DMO) who underwent treatment with Aflibercept in routine clinic settings in ethnically diverse North West London (NWL). In addition, they compared the outcomes reported in the VIVID and VISTA clinical trials. They included 270 eyes of 221 treatment-naïve patients at three NWL hospitals initiated on Aflibercept and who had at least 12 months follow-up. The NWL cohort and participants in the VIVID and VISTA trials were identified to have significant differences at baseline including higher HbA1c and a higher proportion of eyes with proliferative diabetic retinopathy in the NWL cohort. Patients in NWL exhibited meaningfully lower effectiveness of treatment with Aflibercept than was reported in the VIVID and VISTA clinical trials. The likely contributers to lower functional and anatomical outcomes were: a high proportion of patients with good visual acuity at baseline, poorer glycaemic control, worse diabetic retinopathy and under-treatment.